The tweet was deleted by the author.
But we saved everything 🙂.
Monte Rosa Therapeutics will present its latest research on the versatility of molecular glue degraders during an upcoming Endpoints webinar.
The session, featuring Georg Petzold and Chao Quan, will examine how cereblon can engage various targets in drug discovery. Attendees are invited to join the webinar on Tuesday, May 12, at 10:30am EDT. Registration details are provided via the company's official communication channels.
Monte Rosa Therapeutics has previously presented preclinical data on targeting undruggable CCNE1 in solid tumors at AACR26, according to a recent company update. CEO Markus Warmuth is also set to join biopharma experts at AACR2026 to discuss proximity-induced therapies, the company said in a separate announcement. These events reflect Monte Rosa’s continued engagement in advancing targeted protein degradation research.